NCT06326463View on ClinicalTrials.gov

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

July 1, 2030

Study Completion Date

July 1, 2031

Conditions
Hematologic MalignancyALL, ChildhoodAML, ChildhoodLymphomaMDS
Interventions
DRUG

Fludarabine

40mg/m2, Day -4, -3 and -2

DRUG

Cyclophosphamide

"Day -3 and Day-2~REST DAY, -1"

DRUG

CD70-CAR T cell infusion (Autologous)

Day 0 or +1

DRUG

Mesna

Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide

Trial Locations (1)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER